Financial Performance Highlights

Q2 FY27 Standalone Results (Year-over-Year Comparison)

  • Revenue from Operations: ₹795.0 Crore (vs. ₹567.5 Crore in Q2 FY26), growth of 40.1%
  • EBITDA: ₹114.9 Crore (vs. ₹64.0 Crore in Q2 FY26), growth of 79.6%
  • EBITDA Margin: 14.4% (vs. 11.1% in Q2 FY26), expansion of 321 basis points
  • PAT: ₹65.0 Crore (vs. ₹30.0 Crore in Q2 FY26), growth of 116.8%
  • PAT Margin: 8.1% (vs. 5.2% in Q2 FY26), expansion of 290 basis points

H1 FY27 Standalone Results (Year-over-Year Comparison)

  • Revenue from Operations: ₹1,551.3 Crore (vs. ₹1,119.2 Crore in H1 FY26), growth of 38.6%
  • EBITDA: ₹226.6 Crore (vs. ₹133.5 Crore in H1 FY26), growth of 69.7%
  • EBITDA Margin: 14.5% (vs. 11.8% in H1 FY26), expansion of 270 basis points
  • PAT: ₹129.5 Crore (vs. ₹64.0 Crore in H1 FY26), growth of 102.5%
  • PAT Margin: 8.3% (vs. 5.6% in H1 FY26), expansion of 263 basis points

Segment Performance Highlights

Pharmaceuticals Business

  • Non-Ibuprofen portfolio registered approximately 70% year-on-year revenue growth
  • Non-Ibuprofen products accounted for 45% of pharmaceutical revenue in Q2 FY27 (vs. 38% in Q2 FY26)
  • Healthy demand across the pharmaceutical portfolio

Chemicals Business

  • Significant improvement in performance with healthy demand across products
  • Segment's EBIT contribution increased to approximately 7% (vs. 1% in Q2 FY26)
  • Improvement driven by better realizations and operating performance

Management Commentary

Mr. Vikas Gupta, Joint Managing Director, commented on the performance:

  • Performance supported by healthy demand across key products and improved operational efficiencies
  • Diversified business model helped sustain growth momentum amid geopolitical uncertainties and evolving global market conditions
  • Better product mix and operating efficiencies contributed to margin expansion
  • Forward integration into CDMO and formulation manufacturing is a natural extension of process expertise
  • Priorities include portfolio diversification, operational excellence, and expanding presence in higher-value manufacturing
  • Company aims to provide wider range of solutions to existing customers and deepen business relationships

Company Background

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP) is:

  • Established in 1986, headquartered in Ludhiana, Punjab
  • Leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals
  • World's largest producer of Ibuprofen with 30% global market share
  • Among largest global producers of Iso Butyl Benzene (IBB)
  • Key manufacturer of Ethyl Acetate in India
  • API portfolio spans pain management, anti-convulsants, anti-diabetics, and cardiovascular care
  • Exports to over 80 countries including USA, UK, China, and Germany
  • Has strong regulatory approvals and backward-integrated operations

Safe Harbor Statement

The document contains forward-looking statements subject to risks and uncertainties including industry downtrend, political and economic changes, tax laws, litigation, labor relations, exchange rate fluctuations, technological changes, and other factors. The company does not guarantee fulfillment of these statements and undertakes no obligation to update them.